D

DIAGENS

Biotech & Life Sciences · Hangzhou, China · Founded 2016 · IPO 2026

DIAGENS, the operating brand for Hangzhou Deshi Biotechnology Co., Ltd., is a medical technology firm focused on reproductive health and medical imaging AI. The company was established in September 2016 by Dr. Song Ning, who serves as the chairman and general manager. Dr. Song possesses a multidisciplinary background in computer science, life sciences, and clinical medicine, holding a Ph.D. in medicine from Nagasaki University in Japan. His academic and professional journey, which includes teaching positions at Nagasaki University and Shanghai Jiao Tong University School of Medicine, steered him towards addressing challenges in genetic testing, leading to the founding of DIAGENS to industrialize his research. The company's core business revolves around developing and providing solutions that tackle key issues in human reproductive health, primarily through advanced diagnostics. DIAGENS operates in the medical diagnostics market, serving over 400 hospitals and medical institutions, including many top-tier hospitals and diagnostic centers in China. Its business model includes the sale of intelligent medical equipment, a Model-as-a-Service (MaaS) cloud platform, and providing localized self-training solutions for its clients. Since its angel round financing in late 2016, the company has successfully completed multiple funding rounds, including a Series C+ round, attracting significant investment from various capital firms. DIAGENS has developed a portfolio of products built upon its proprietary universal medical imaging foundation model, iMedImage™. A key product is the AI AutoVision® Chromosome Karyotype Assisted Diagnosis System, which automates the entire process of chromosome analysis, from segmentation and counting to identifying abnormalities. This system significantly reduces the report turnaround time for chromosome analysis from about 30 days to 4-7 days. The company's product line also includes a complete automated workflow for cytogenetics, featuring the KayoFlow® series for automated cell harvesting and slide preparation, and the MetaSight® system for automated microscopic image scanning. In addition to its AI-driven diagnostic systems, DIAGENS produces consumables for assisted reproduction, such as ICSI micro-injection needles and holding pipettes, aiming to provide a domestic alternative to foreign-monopolized technologies. Keywords: medical imaging AI, reproductive health, cytogenetics, chromosome analysis, genetic testing, in-vitro diagnostics, assisted reproduction technology, AI diagnostics, Dr. Song Ning, automated karyotyping, medical devices, birth defect prevention, Hangzhou Deshi Biotechnology, iMedImage, AutoVision, MetaSight, KayoFlow, prenatal diagnosis, hematology, cell harvesting